For Renal Studies
Table: Cold kits – For Renal Studies
  • In vivo kit

    Product Code

    ATC code

    Marketing Authorisation No.

    For preparation of

    Active ingredient

    Content/vial

    Excipients

    Indications

    Activity for labelling vial

    Vials per kit

    Recommended doses

    Shelf life

    Storage

    SPC

  • DMSA 1.5 mg

    Tc-IK-7

    V09CA02

    OGYI-T9245/01

    Technetium (99mTc) succimer injection

    Dimercaptosuccinic acid

    1.5 mg

    • Stannous chloride dihydrate
    • Ascorbic acid
    • Calcium gluconate
    • Kidney scintigraphy, static kidney imaging, localisation of the
      kidneys with imaging
    • Determination of the functional mass of the kidney
    • Determination of the relative function ratio (percentage) of the
      left and right kidneys

    1.0–1.8 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    24 months
    after radiolabelling: 8 h

    2-8°C
    after radiolabelling: ≤ 25°C

  • DTPA 9 mg

    Tc-IK-8

    V09CA01

    OGYI-T-9244/01

    Technetium (99mTc) pentate injection

    Diethylenetriamino pentaacetic acid

    9.0 mg

    • Stannous chloride dihydrate
    • Ascorbic acid
    • Sodium chloride
    • Dynamic studies of kidney, determination of kidney perfusion,
      glomerural filtration rate, total and partial kidney function
    • Examination of the cerebral blood circulation
    • Examination of the gastrointestinal tract by using labelled
      foodstuff or drink
    • Examination of liquor circulation

    0.8–2.4 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    12 months
    after radiolabelling: 8 h

     ≤ 25°C
    after radiolabelling: ≤ 25°C

  • EC 2 mg

    Tc-IK-25

    V09CA

    OGYI-T-9141/01

    Technetium (99mTc) EC injection

    Ethylene-dicysteine

    2.0 mg

    Vial A

    • Disodium hydrogen phosphate dihydrate
    • Mannitol
    • Ascorbic acid
    • Sodium edetate

    Vial B

    • Stannous chloride dihydrate
    • Ascorbic acid
    • Tartaric acid

    Vial C

    • Potassium dihydrogen phosphate
    • Ascorbic acid
    • Dynamic studies of kidney for renal tubular function

    0.8–1.6 GBq

    3 x 4 injection vials

    See in the Summary of Product Charasteristics

    12 months
    after radiolabelling: 8 h

    2-8°C
    after radiolabelling: ≤ 25°C

For Blood Pool
Table: Cold kits – For Blood Pool
  • In vivo kit

    Product Code

    ATC code

    Marketing Authorisation No.

    For preparation of

    Active ingredient

    Content/vial

    Excipients

    Indications

    Activity for labelling vial

    Vials per kit

    Recommended doses

    Shelf life

    Storage

    SPC

  • PYRON 25 mg

    Tc-IK-5

    V09BA03

    OGYI-T9246/01

    Technetium (99mTc) tin pyrophosphate injection

    Sodium pyrophosphate

    25.0 mg

    • Stannous chloride dihydrate
    • Sodium chloride
    • Bone and acute myocardial infarct scintigraphy
    • Blood pool scintigraphy
    • Spleen scintigraphy

    1.3–3.0 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    12 months
    after radiolabelling: 3 h

    ≤ 25°C
    after radiolabelling: ≤ 25°C

For Bone Scintigraphy
Table: Cold kits – For Bone Scintigraphy
  • In vivo kit

    Product Code

    ATC code

    Marketing Authorisation No.

    For preparation of

    Active ingredient

    Content/vial

    Excipients

    Indications

    Activity for labelling vial

    Vials per kit

    Recommended doses

    Shelf life

    Storage

    SPC

  • MDP 5 mg

    Tc-IK-10

    V09BA02

    OGYI-T9702/01

    Technetium (99mTc) medronate injection

    Medronic acid

    5.0 mg

    • Stannous chloride dihydrate
    • Ascorbic acid
    • Urea

    For bone scintigraphy (diagnostic skeletal imaging)

    Use of the preparation is highly recommended for:

    • Primer bone tumours
    • Metastases of other tumours, for example prostate/breast/lung cancer
    • Osteomyelitis
    • Metabolic bone diseases
    • Paget’s disease

    3.0–6.0 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    12 months
    after radiolabelling: 6 h

    2-8°C
    after radiolabelling: ≤ 25°C

For Myocardial Perfusion Scintigraphy
Table: Cold kits – For Myocardial Perfusion Scintigraphy
  • In vivo kit

    Product Code

    ATC code

    Marketing Authorisation No.

    For preparation of

    Active ingredient

    Content/vial

    Excipients

    Indications

    Activity for labelling vial

    Vials per kit

    Recommended doses

    Shelf life

    Storage

    SPC

  • MIBITop 1 mg

    Tc-IK-81

    V09GA01

    OGYI-T-23814/01

    Technetium (99mTc) sestamibi injection

    [tetrakis (1-isocyanide-2-methoxy-2-methylpropyl-)copper(I)] tetrafluoroborate

    1.0 mg

    • Cysteine hydrochloride monohydrate
    • Sodium citrate
    • Stannous chloride dihydrate
    • D-Mannitol
    • Myocardial perfusion scintigraphy for the detection and localisation of coronary artery disease (angina
      pectoris and myocardial infarction)
    • Assessment of global ventricular function.First-pass technique for determination of ejection fraction and/or ECG-triggered, gated SPECT for
      evaluation of left ventricular ejection fraction, volumes and regional wall motion
    • Scintimammography for the detection of suspected breast cancer when mammography is equivocal, inadequate
      or indeterminate
    • Localisation of hyperfunctioning parathyroid tissue in patients with recurrent or persistent disease in
      both primary and secondary hyperparathyroidism, and in patients with primary hyperparathyroidism scheduled
      to undergo initial surgery of the parathyroid glands.

    max. 15.0 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    24 months
    after radiolabelling: 16 h

    2-8°C
    after radiolabelling: ≤ 25°C

For Examination of the Liver- and Hepatobiliary System
Table: Cold kits – For Examination of the Liver- and Hepatobiliary System
  • In vivo kit

    Product Code

    ATC code

    Marketing Authorisation No.

    For preparation of

    Active ingredient

    Content/vial

    Excipients

    Indications

    Activity for labelling vial

    Vials per kit

    Recommended doses

    Shelf life

    Storage

    SPC

  • FYTON 15 mg

    Tc-IK-2

    V09DB07

    OGYI-T9288/01

    Technetium (99mTc) phytate injection

    Sodium phytate

    15.0 mg

    • Stannous chloride dihydrate
    • Sodium chloride
    • Morphological examination of the liver by imaging technique
    • Diagnosis of benign and malignant liver tumours and monitoring of the therapy
    • Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct,
      etc.)

    0.8–1.6 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    12 months
    after radiolabelling: 3 h

    ≤ 25°C
    after radiolabelling: ≤ 25°C

  • TECHIDA 30 mg

    Tc-IK-6

    V09DA02

    OGYI-T-9210/01

    Technetium (99mTc) etifenin injection

    Diethyl-acetanilid-imino diacetic acid

    30.0 mg

    • Stannous chloride dihydrate
    • Ascorbic acid
    • Dynamic examination of the function of the hepatocytes
    • Liver transplant evaluation
    • Dynamic examination of flow disorders in the hepatobiliary system (blockage in the biliary duct, etc.)
    • Examination of the acute cholecystitis
    • Diagnosis of focalis nodular hyperplasia

    0.8–1.6 GBq

    6 injection vials

    See in the Summary of Product Charasteristics

    24 months
    after radiolabelling: 6 h

    2-8°C
    after radiolabelling: 2-8°C


Table: I-131 hard capsules for diagnosis and therapy

  • Product name

    Product code

    ATC code

    Marketing Auth. No.

    Pharmaceutical Form and Description

    Activity per capsule

    Radionuclidic purity

    Radiochemical purity

    Expiry time

    Indications and Phosology

    Storage

    Packaging

  • ThyroTop D 0.5-37 MBq hard capsule complies with the European Pharmacopoeia 0938 monograph

    I-RA-7/D

    V09F

    OGYI-T-9681/05

    Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131
    labelled sodium iodide, for oral administration.

    0.5-37 MBq

    131I ≥ 99.9 %

    ≥ 95 %

    21 days from the manufacturing date

    Thyroid diagnostics

    • 0.2-0.5 MBq capsule for radioiodine uptake of thyroid in case no accurate dosimetry is
      needed.
    • 2-4 MBq capsule can be used for calculation of personalised dose for the radionuclide
      therapy and thyroid scintigraphy for the establishment of the size of the hyperfunctioning
      tissue in thyroid nodules.
    • For whole body radioiodine scintigraphy in differentiated thyroid cancer 37-185 MBq
      (usually 74-111 MBq) I-131 is needed. 2-3 capsules should be administered per os.

    Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation
    safety.

    1-10 capsules in type I injection vial, closed with brombutyl stopper and green aluminium cap in lead
    container with paper insert.

  • I-131-sodium-iodide ThyroTop 38-7400 MBq hard capsules complies with the European Pharmacopoeia
    2116 monograph

    I-RA-7/K

    V10XA01

    OGYI-T-9681/01

    Hard capsule, size “0”, colourless, transparent, CONI-SNAP type gelatine capsule, containing I-131
    labelled sodium iodide, for oral administration.

    38-7400 MBq

    131I ≥ 99.9 %

    ≥ 95 %

    21 days from the manufacturing date

    Radionuclide therapy

    Treatment of hyperthyreosis

    • Graves disease.
    • Hyperfunctioning adenoma.
    • Non immunogenic diffuse goiter.

    Treatment of thyroid carcinoma

    • Ablation of residual thyroid tissues following thyroid cancer surgery and treatment of
      recidivations and metastases.
    • Required amount of activity is administered per os in one or max. 2 capsules

    Do not store above 25 ºC. Store in the original packaging. Comply with the regulations for radiation
    safety.

    1 capsule in a plastic insert with screwed cap placed into a lead container with wall thickness of
    15-38 mm.

Table: Irradiators

  • OB-SERVO

    Classification

    IAEA Category

    Storage Type

    Source Details

    Sealed Source

    Maximum Activity

    Source Type

    Source Dimensions

    Source Cage Type

    Source Cage Capacity

    Configuration

    Radiation details

    Maximum Central Dose Rate

    Dose Uniformity (Max)

    Dose Rate at 1 m

    Accessories

    Pressurized Air Supply

    Ventilation System

    Water Treatment

    Safety and Security System

    Control System

    Electric Requirements

  • IGNIS

    Research

    Category I.

    Dry Storage

     

    Co-60

    888 TBq
    (24 kCi)

    CoS-44 HH-N

    Ø11×220 mm

    Cylindrical

    48 pcs

    Fixed sources with rotating canister

     

    10 kGy/h

    ± 20%

     

    50 Hz, 230 V – with ground (Single-Phase Power)

  • SANGUIS

    Research

    Category I.

    Dry Storage

     

    Co-60

    444 TBq
    (12 kCi)

    CoS-44 HH-N
    CoS-45 HH
    CoS-57 HH

    Ø11×220 mm
    Ø11×81.5 mm
    Ø23.5×36.5 mm

    Cylindrical

    8 pcs

    Source turn (absorbent unit) and rotating canister

     

    2.5 kGy/h

    ± 20%

     

    50 Hz, 230 V – with ground (Single-Phase Power)

  • LA/D

    Research and Calibration

    Category II.

    Dry Storage

    Co-60

    111 TBq
    (3 kCi)

    CoS-57 HH

    Ø23.5×36.5 mm

    Special Drawer

    1 pc

    Source hoist with collimator and absorbent unit

    30 Gy/h

    50 Hz, 230 V – with ground (Single-Phase Power)

  • D

    Semi – Multipurpose

    Category II.

    Dry Storage

    Co-60

    3700 TBq
    (100 kCi)

    CoS-44 HH-N

    Ø11×220 mm

    Special Drawer

    12 pcs

    Source hoist with turntable system

    1 kGy/h

    50 Hz, 230 V – with ground (Single-Phase Power)

  • W

    Semi – Multipurpose

    Category IV.

    Wet Storage

    Co-60

    7400 TBq
    (200 kCi)

    CoS-43
    HH-M
    CoS-44 HH-N

    Ø11×451 mm,
    Ø11×220 mm

    Cylindrical

    20 pcs

    Source hoist with turntable system

    1.5 kGy/h

    50 Hz, 230 V – with ground (Single-Phase Power)

Table: I-131 MIBG 20 MBq/ml injection for diagnostic use

  • Product code

    Pharmaceutical form and description

    Activity per vial

    Specific activity

    Radioactive concentration

    Radionuclid impurities

    Radiochemical purity

    pH

    Expiry date

    Indications and posology

    Recommended dose

    Storage

    Packaging

  • I-RAO-1

    Radioactive sterile injection solution.
    The active ingredient of the radioactive solution for
    injection for intravenous use is I-131 radioisotope labelled meta-iodobenzyl-guanidine (MIBG).

    20 MBq, 40 MBq, or 80 MBq at activity reference date and time

    ≥ 26.7 GBq/g MIBG at activity reference date and time

    20 MBq/ml at activity reference date and time

    ≤ 0.1%

    ≥ 95%

    5–7

    5 days from manufacturing date

    Indication field: radioisotope diagnostics
    Localisation and imaging of neuroendocrine tumours, especially:phaeochromocytomaneuroblastoma

    The recommended individual patient dose is 20–40 MBq I-131-MIBG

    To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended
    before the examination. The injection should be administered slowly; time of administration is 2-4
    minutes.

    Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or
    asthmatic spasms.

    Store in refrigerator at 2–8°C. Comply with the regulations for radiation safety.

    In type I injection vial (6R) closed with brombutyl stopper and green aluminium cap in lead container
    with paper insert.

    Transported in a Type A package

Table: I-131 MIBG 370 MBq/ml injection for therapy

  • Product code

    Pharmaceutical form and description

    Activity per vial

    Specific activity

    Radioactive concentration

    Radionuclid impurities

    Radiochemical purity

    pH

    Expiry date

    Indications and posology

    Recommended dose

    Storage

    Packaging

  • I-RAO-2

    Radioactive sterile solution for injection.

    For intravenous use. The active ingredient of the radioactive solution for injection for intravenous
    use is I-131 radioisotope labelled meta-iodobenzylguanidine (MIBG)

    3300-4100 MBq at activity reference date and time

    ≥ 555 GBq/g at activity reference date and time

    333-410 MBq/ml at activity reference date and time

    ≤ 0.1%

    ≥ 90%

    5-5.5

    5 days from manufacturing date

    RADIOISOTOPE THERAPY

    Local, lesion-specific treatment of neuro-endocrine tumours, especially:

    • phaeochromocytoma
    • neuroblastoma
    • paraganglioma
    • medullar thyroid carcinoma
    • carcinoid

    The recommended individual dose is 3.3–4.1 GBq.

    To prevent the uptake of the free radioiodine evolving in vivo, thyroid blockade is recommended
    before the examination.

    Do not administer the injection directly. 10 ml of the MIBG solution for injection must be mixed with
    90 ml of 5% glucose injection. The obtained solution which has a total volume of 100 ml should be
    administered to the patient slowly. Time of administration is 2 – 4 hours.

    Rapid administration of MIBG can result in blood pressure increase, allergic symptoms, flush or
    asthmatic spasms.

    Store in a freezer, below -18°C. Storage of radiopharmaceuticals should be in accordance with
    national regulation on radioactive material. To ensure the low temperature during shipping dry-ice
    is used to cool the container.

    In type I injection vial (10R), closed with brombutyl stopper and green aluminium cap in lead
    container with paper insert.

    Transported in a Type A package

Table: I-131 sodium iodide solutions, drug substances supported with Active Substance Master File

  • Product name

    Product code

    Description

    Volume

    Radioactive concentration

    Radionuclidic purity

    Radiochemical purity

    pH

    Expiry time

    Other information

    Storage

    Packaging

  • I-131 sodium iodide sterile solution, drug substance according to European Pharmacopoeia 0281
    monograph

    I-RA-7

    Clear, colourless and sterile solution of 131I sodium iodide containing iodine-131 in the form of
    sodium idoide in Na2CO3/NaHCO3/NaOH buffer and 0.5-2 mg/ml sodium thiosulphate solution, reducing
    agent diluted accoring to the cusomer specified active concentration. Bacterial endotoxins <100
    IU/ml.

    Non-carrier added

    0.2 – 10.0 ml

    0.1 – 55.5 GBq/ml

    131I ≥ 99.9 %

    ≥ 95 %

    7 – 10

    21 days from manufacturing date

    Active pharmaceutical ingredient for manufacture of radiopharmaceuticals by dilution with water or by
    for capsule preparation.

    For oral administration.

    Store at room temperature in its own container, in accordance with the regulations on radioactive
    materials.

    In type I injection vial (6R or 10 R), closed with brombutyl stopper and green aluminium cap in lead
    container with paper insert (Type A packaging).

    Pack size: ≤ 29.6 GBq (at the indicated calibration date)/vial

  • I-131 sodium iodide non-sterile solution, drug substance for radiolabelling according to European
    Pharmacopoeia 02121 monograph

    I-RA-5

    Clear, colourless and non-sterile solution of 131I sodium iodide containing iodine-131 in the form of
    sodium iodide in Na2CO3/NaHCO3/NaOH buffer diluted with 0.0001M NaOH according to the customer
    specified active concentration.

    Non-carrier added. No reducing agents added.

    0.2 – 10.0 ml

    ≥ 0.1-55.5 GBq/ml

    131I ≥ 99.9 %

    ≥ 95 %

    8 – 11

    21 days from manufacturing date

    Active ingredient for manufacture of radiopharmaceuticals by dilution – e.g. with water or buffer for
    labelling purposes or capsule preparation, for oral administration.

    Store at room temperature in its own container, in accordance with the regulations on radioactive
    materials.

    In type I injection vial (6R or 10 R), closed with brombutyl stopper and green aluminium cap in lead
    container with paper insert (Type A packaging).

    Pack size: ≤ 111 GBq (at the indicated calibration date)/vial

Table: I-125 Radiochemicals

  • Product code

    Description

    Specific activity

    Radioactive concentration

    Radionuclid impurities

    Radiochemical purity

    pH

    Calibration date

    Expiry date

    Storage

    Packaging

  • I-RB-4

    Clear, colourless solution containing I-125 sodium iodide in NaOH. Non-carrier added. No reducing agents added

    ≥ 600 GBq/mg

    ≤ 3669 MBq/ml

    I-126 ≥ 0.005%

    ≥ 95%

    8 – 11

    13 days

    60 days from dispatch

    Store at room temperature in its own container, in accordance with the regulations on radioactive materials.

    Supplied in plastic vial placed in a lead container (KT 1-3).

    The lead container is packed in a labelled easy-open metal can, which contains plastic insert.

    Transported in a Type A packaging in accordance with IATA regulation.

  • I-RB-41

    Clear, colourless solution containing I-125 sodium iodide in NaOH. Non-carrier added. No reducing agents added

    ≥ 600 GBq/mg

    ≥ 3700 MBq/ml

    I-126 ≥ 0.005%

    ≥ 95%

    8 – 11

    13 days

    60 days from dispatch

    Store at room temperature in its own container, in accordance with the regulations on radioactive materials.

    Supplied in plastic vial placed in a lead container (KT 1-3).

    The lead container is packed in a labelled easy-open metal can, which contains plastic insert.

    Transported in a Type A packaging in accordance with IATA regulation.

Table: Distributed Products

  • SPECIFICATIONS

    Standards

    Density Measurement Range

    Moisture Measurement Range

    Density Source

    Moisture Source

    Density Source Activity

    Moisture Source Activity

    PRECISION

    BS one-minute test

    Transmission one-minute test

    Moisture one-minute test

    CHEMICAL COMPOSITION ERROR

    Backscatter

    Transmission

    SURFACE ROUGHNESS ERROR (0.05 in. 100% void)

    Backscatter

    Transmission

    OPERATING TEMPERATURE

    Ambient

    Surface

    Power Source

    Battery Life

    Display

    Memory Storage

    Gauge Size

    Weight

    Shipping Weight

  •  

    ASTM D6938, D2950, D7013, D7759, C1040 and AASHTO T310

    70 to 170 pcf
    (1.120 to 2.73 gcc)

    0 to 40 pcf (0 to 0.64 gcc)

    Cesium 137

    Americium 241: Beryllium

    Maximum (10 mCi) 370 Mbq

    Maximum (50 mCi) 1.85 GBq

     

    ±0.50 pcf (0.008 gcc)(at 125 pcf)

    ±0.25 pcf (0.004 gcc)(at 125 pcf)

    ±0.25 pcf (0.004 gcc)(at 10 pcf)

     

    ±1.00 pcf (0.016 gcc)

    ±0.75 pcf (0.012 gcc)

     

    – 4.00 pcf (0.064 gcc)

    – 0.50 pcf (0.008 gcc)

     

    – 14° to 167°F (-10° to 75°C)

    Up to 350°F (175°C)

    6-Cell AA NiMH battery pack with a single 9V alkaline for backup

    500-1000 recharge/discharge cycles

    Large 4 line X 20 character LCD display with 9mm tall characters

    10 Projects with 40 readings each

    26.7″ H X 14.1″ W X 9.8″ D
    (67.8 x 35.8 x 24.8 cm)

    28.5 lbs (13 kg)

    90 lbs (40.82 kg)

Table: Immunoassay – Tumour Markers

  • Product code

    Product name

    Pack size (Test)

    IFU/EN

    IFU/ES

    IFU/RU

  • RK-800CT

    AFP [I-125] IRMA KIT

    [100]

  • RK-760CT

    ßhCG [I-125] IRMA KIT

    [100]

  • RK-820CT

    free ßhCG [I-125] IRMA KIT

    [100]

  • RK-38CT

    hCEA [I-125] IRMA KIT

    [100]

  • RK-10CT

    hPSA [I-125] IRMA KIT

    [100]

  • RK-85CT

    free PSA [I-125] IRMA KIT

    [100]

  • RK-125CT

    CA125 [I-125] IRMA KIT

    [100]

  • RK-199CT

    CA 19-9 [I-125] IRMA KIT

    [100]

  • RK-153CT

    CA 15-3 [I-125] IRMA KIT

    [100]

  • RK-724CT

    CA 72-4 [I-125] IRMA KIT

    [100]

  • RK-211CT

    CYFRA 21.1 IRMA KIT

    [100]

  • RK-300CT

    NSE [I-125] IRMA kit *

    [100]

* =on request product / minimum order: 5 kits

Table: Immunoassay – Diabetes

  • Product code

    Product name

    Pack size (Test)

    IFU/EN

    IFU/ES

    IFU/RU

  • RK-84CT

    hC-peptide [I-125] IRMA KIT

    [100]

  • RK-400CT

    INSULIN [I-125] IRMA KIT

    [100]

  • RK-20P100

    Anti-IA2 RIA KIT

    [100]

  • RK-40P100

    Anti-GAD65 RIA KIT

    [100]

  • RK-50P100

    IAA RIA KIT

    [100]

  • RK-20P50

    Anti-IA2 RIA KIT

    [50]

  • RK-40P50

    Anti-GAD65 RIA KIT

    [50]

  • RK-50P50

    IAA RIA KIT

    [50]

Table: Immunoassay – Thyroid Functions

  • Product code

    Product name

    Pack size (Test)

    IFU/EN

    IFU/ES

    IFU/RU

  • RK-83CT

    hCalcitonin [I-125] IRMA KIT

    [100]

  • RK-8CT

    Anti-hTG [I-125] RIA KIT

    [100]

  • RK-51CT

    hTG [I-125] IRMA KIT

    [100]

  • RK-36CT

    Anti-hTPO [I-125] RIA KIT

    [100]

  • RK-1CT1

    Turbo TSH [I-125] IRMA KIT

    [100]

  • RK-1CT5

    Turbo TSH [I-125] IRMA KIT

    [500]

  • RK-339CT

    FT3 [I-125] RIA KIT

    [100]

  • RK-349CT

    FT4 [I-125] RIA KIT

    [100]

  • RK-11CT1

    T4 [I-125] RIA KIT

    [100]

  • RK-609CT

    T3 [I-125] RIA KIT

    [100]

  • RK-950CT

    T3 UPTAKE [I-125] RIA KIT

    [100]

Table: Immunoassay – Steroid Hormones

  • Product code

    Product name

    Pack size (Test)

    IFU/EN

    IFU/ES

    IFU/RU

  • RK-460CT

    PROGESTERONE [I-125] RIA KIT

    [100]

  • RK-61CT

    TESTOSTERONE [I-125] RIA KIT

    [100]

  • RK-240CT

    CORTISOL [I-125] RIA KIT

    [100]

  • RK-620CT

    DHEA-SO4 [I-125] RIA KIT

    [100]

Table: Immunoassay – Serum Proteins

  • Product code

    Product name

    Pack size (Test)

    IFU/EN

    IFU/ES

    IFU/RU

  • RK-5CT

    hGH [I-125] IRMA KIT

    [100]

  • RK-750CT

    hLH [I-125] IRMA KIT

    [100]

  • RK-780CT

    hPRL [I-125] IRMA KIT

    [100]

  • RK-790CT

    hFSH [I-125] IRMA KIT

    [100]

  • RK-4CT

    PAPP-A [I-125] IRMA kit

    [100]

  • RK-86CT

    SHBG [I-125] IRMA KIT

    [100]

  • RK-900CT

    FERRITIN [I-125] IRMA KIT

    [100]

Table: Radiation Protection Systems – HK Marked Group of Products

  • Sign

    Activity of the
    Transportable Material (Co-60)
    [GBq]

    Inner Size of the
    Storage Unit
    [mm]

    Weight of Package
    Container/Package/Gross
    [kg]

  • HK-5

    5

    50 x 50

    70/145/215

  • HK-10

    10

    50 x 150

    230/140/370

  • HK-40

    40

    50 x 150

    420/140/560

  • HK-400

    400

    80 x 150

    640/135/775

Table: Other Labelled Products – Carbon-14

  • Code

    Product
    specific activity: 370 – 1850 MBq /mmol

    Unlabelled
    CAS number

  • CC-502

    N-Acetyl-2-chloro-[U-14C]aniline

    533-17-5

  • CC-501

    N-Acetyl-2-nitro-[U-14C]aniline

    552-32-9

  • CC-509

    [U-14]Benzenesulfonyl chloride

    98-09-9

  • CC-563

    1,3-Bis(4-nitro-[U-14]phenyl)urea; DNC, [ring-U-14]

    587-90-6

  • CC-566

    4-Bromo-N,N-dimethyl-[U-14C]aniline

    586-77-6

  • CC-528

    i-[1-14C]Butyric acid hydrazide

    3619-17-8

  • CC-543

    4-Chloro-[ring-U-14C]benzoic acid

    74-11-3

  • CC-439

    Copper(I) [14C]cyanide

    544-92-3

  • CC-591

    [2-14C]Cyclohexane-1,3-dione

    504-02-9

  • CC-590

    3,4-Dichloro-[U-14C]aniline

    95-76-1

  • CC-507

    2,4′-Dichloro-[carbonyl-14C]benzophenone

    85-29-0

  • CC-511

    2,4′-Dichloro-[4′-chlorophenyl-U-14C]benzophenone

    85-29-0

  • CC-592

    [1,2-14C]Dichloroethane

    107-06-2

  • CC-521

    2,5-Dichloro-[U-14C]phenol

    583-78-8

  • CC-506

    3,4-Dimethyl-[U-14C]aniline

    95-64-7

  • CC-520

    4-Fluoro-[ring-U-14C]acetanilide

    351-83-7

  • CC-564

    2-Hydroxy-4,6-dimethyl-[2-14C]pyrimidine; HDP, [2-14C]

    108-79-2

  • CC-595

    4-Iodo-nitro[U-14C]benzene

    636-98-6

  • CC-508

    [2-14C]Isopropyl-triphenyl-phosphonium iodide

    24470-78-8

  • CC-515

    Medetomidine, [imidazole-2-14C]

    86347-14-0

  • CC-517

    Medetomidine, [phenyl U-14C]

    86347-14-0

  • CC-561

    4-Methyl-[ring-U-14C]acetophenone

    122-00-9

  • CC-513

    Methyl 2-pyrimidine[14C]carboxylate

    34253-03-7

  • CC-519

    [carboxyl-14C]Nicotinic acid

    59-67-6

  • CC-594

    2-Nitro-[U-14C]aniline

    88-74-4

  • CC-518

    4-Nitro-[U-14C]aniline

    100-01-6

  • CC-505

    4-Nitro-[formyl-14C]benzaldehyde

    555-16-8

  • CC-18

    4-Nitro-[U-14C]phenol

    100-02-7

  • CC-237

    Phenyl-[1-14C]acetic acid

    103-82-2

  • CC-471

    2-Phenyl-[1-14C]propionic acid

    492-37-5

  • CC-461

    2-[ring-U-14C]Phenylpropionic acid

    492-37-5

  • CC-510

    Potassium [14C]thiocyanate

    333-20-0

  • CC-523

    Sulfadiazine, [phenyl ring-U-14C]

    68-35-9

  • CC-476

    Sulfamethoxazole, [phenyl ring-U-14C]

    723-46-6

  • CC-195

    [1,4-14C]Succinic acid

    110-15-6

  • CC-468

    Tilmicosin, [3,5-dimethylpiperidin-1-yl-3,5-14C]

    108050-54-0

  • CC-522

    4-[ring-U-14C]Toluic acid

    99-94-5

  • CC-495

    1,2,4-Trichloro-[U-14C]benzene

    120-82-1

  • CC-553

    Triethyl phosphono[1-14C]acetate

    867-13-0

  • CC-499

    2-Trifluoromethyl-[ring-U-14C]benzoic acid

    433-97-6

  • CC-361

    Troglitazone, [thiazolidin-2,4-dione 2-14C]

    97322-87-7

  • CC-426

    Zinc [14C]cyanide

    557-21-1

Table: Research immunoassay kits – Rat Hormones

  • Code

    Test

    Pack Size (Tests)

    IFU

  • RK-547

    rInsulin RIA kit *

    120

  • RK-547CT

    rInsulin IRMA kit coated tube version

    100

  • EK-547

    rInsulin ELISA kit

    96

  • RK-548

    rCorticosterone RIA kit

    120

  • RK-548CT

    rCorticosterone RIA kit coated tube version

    100

  • EK-548

    rCorticosterone ELISA kit

    96

  • RK-550

    rFSH (rat follicle stimulating hormone) RIA kit

    120

  • RK-551

    rGH (rat growth hormone) RIA kit

    120

  • RK-552

    rLH (rat luteinizing hormone) RIA kit

    120

  • RK-553

    rPRL (rat prolactin) RIA kit*

    120

  • RK-554

    rTSH (rat thyroid stimulating hormone) RIA kit

    120

  • RK-554Cset

    rTSH (rat thyroid stimulating hormone) RIA kit Control set

  • EK-547Cset

    rInsulin ELISA kit Control set

*On request

List of scientific publications HERE

Table: Research immunoassay kits – Human Research Kits

  • Code

    Test

    Pack Size (Tests)

    IFU

  • RK-509

    cAMP (adenosine 3′,5′-cyclic monophosphate) RIA kit*

    100

  • RK-512

    αANP (human α-atrial natriuretic peptide) RIA kit *

    100

  • RK-518

    C3a (human complement C3a des Arg) RIA kit

    150

  • RK-518Cset

    C3a (human complement C3a des Arg) RIA kit Control set

  • RK-519

    C4a (human complement C4a des Arg) RIA kit

    150

  • RK-519Cset

    C4a (human complement C4a des Arg) RIA kit Conrol set

  • RK-520

    C5a (human complement C5a des Arg) RIA kit

    150

  • RK-525

    cGMP (guanosine 3′,5′-cyclic monophosphate) RIA kit*

    100

  • RK-535

    Endothelin-1,2 RIA kit *

    100

  • RK-545

    Endothelin-1,2 high sensitivity RIA kit *

    100

  • RK-555

    Endothelin 1-21 RIA kit *

    100

* On request

Table: Research immunoassay kits – Human IVD kits useful for Animal Science Research

  • Bovine

    Ovine

    Caprine

    Equine

    Porcine

    Rabbit

    Rodents

    Poultry

    Monkey

    Fish

List of scientific publications HERE